Información de la revista
Vol. 113. Núm. 7.
Páginas 750-753 (Julio - Agosto 2022)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 113. Núm. 7.
Páginas 750-753 (Julio - Agosto 2022)
Case and Research Letter
Open Access
Individualized, Adjuvant-Intensified Immunocryosurgery for the Treatment of Squamous Cell Carcinoma in the Oldest Old: An Exploratory Case Series
Inmunocriocirugía individualizada intensificada con adyuvantes para el tratamiento del carcinoma de células escamosas en el anciano: una serie de casos exploratorios
Visitas
...
G. Gaitanis
Autor para correspondencia
ggaitan@uoi.gr

Corresponding author.
, C. Vlachos, I.D. Bassukas
Department of Skin and Venereal Diseases, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece
Contenido relaccionado
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Figuras (2)
Texto completo
To the Editor,

The approach to the ‘oldest-old’ patients (patients older than 85 years-of-age) with cutaneous squamous cell carcinoma (cSCC) must be adapted to the unavoidable presence of comorbidities, the inevitable decline of the physical and cognitive ability for self-support and the limited life-expectancy.1

cSCC is a potentially life threating tumor that preferentially affects the ‘oldest old’,2 a fact that often instigates individualized approaches. For primary cSCC first-line treatment is surgery either with clinically predefined margins or Mohs.3 However, the increasing frailty of these patients coupled with life-expectancy considerations substantially limit the applicability of radical, curative surgery, increasing the attractiveness of less-invasive, yet effective, therapeutic modalities.4

Herein, we compile the preliminary findings of an open-label study on the treatment of locally confined cSCC in four patients over 85 years old with individualized, patient- and tumor-adapted immunocryosurgery modifications.

Patients were scheduled to be treated with an extended and intensified immunocryosurgery treatment protocol that included a more intense cryosurgery session (open spray liquid N2, 2 freeze-thaw cycles, 30s each vs 15s for BCC5) on days 14 and 28 of daily imiquimod application. Once daily imiquimod was to be resumed already on the same night and to be continued either for three more weeks (‘5/1 scheme’) or until the next cryosurgery session on day 28 and then for three more weeks (7 weeks imiquimod/2 cryosurgery sessions: ‘7/2 scheme’). Addition of optional adjuvants (intralesional methotrexate, tretinoin cream) was decided during the bi-weekly treatment course evaluation. Tretinoin cream 0.05% was added at week 2 only if minimal topical inflammatory tumor response was evident. Likewise, intralesional methotrexate was scheduled for the days of the cryosurgery sessions, yet with anticipated individualized adaptation. Treatment end and scheduled visits were planned as previously.5

Eight biopsy-confirmed cSCC in four patients (3 males: 1 female, median age: 88 years [range: 85–89]) were treated on immunocryosurgery basis (Table 1). Different tumor-treatment trajectories with individualized adaptations of the prototype therapeutic scheme are presented below.

Table 1.

Clinical characteristics and therapeutical parameters of 8 cutaneous squamous cell carcinomas treated with immunocryosurgery (±adjuvants).

Tumor  Patient  Age/gender  Localization  Diameter (mm)  Prior surgery  Treatment cycles  Imiquimod (weeks)  Cryo sessions  Adjuvants  Outcome  Follow-up (months) 
87 Male  Scalp  20  10 years ago  1st cycle: 7; 2nd cycle: 5  1st cycle: 2; 2nd cycle: 1  No  Clearance  42 
85 Female  Cheek, left  15  No  Trea; 2xMTXb (5mg)  Clearance  14 
  Temple, left  11  No  Tre; 2xMTX (5mg)  Clearance  14 
  Cheek, right  No  Tre  Clearance  12 
  Nose, left  No  Tre  Clearance  12 
87 Male  Scalp  30  No  1st cycle: 5; 2nd cycle: 5  1st cycle 1; 2nd cycle: 1  1st cycle: 1xMTX (5mg); 2nd cycle: None  Clearance  12 
  Scalp  25  No  1xMTX (5mg)  Clearance 
89 Male  Cheek, left  22  No  1st cycle: 9; 2nd cycle: 5  1st cycle: 3; 2nd cycle: 2  1st cycle: 3xMTX(5mg); 2nd cycle: 2xMTX(5mg)  Partial response-relapse 

Abbreviations.

a

Tre: tretinoin cream.

b

MTX: methotrexate.

Patient 1 (Fig. 1) was initiated with a ‘7/2 immunocryosurgery cycle’ with a partial tumor response (Fig. 1B). The tumor was eradicated with an additional, modified, ‘5/1 immunocryosurgery cycle’ (5-weeks imiquimod with an additional cryosurgery session at the last, 35th cycle's day, Fig. 1C) and remained relapse free 30 months thereafter (Fig. 1D).

Figure 1.

Panel (A): Initial presentation of the Tumor 1 in the mid-scalp (Patient 1). The tumor had a maximal diameter of 20mm and was a relapse from a previous surgery 10 years ago. Panel (B): After the initial ‘7/2 treatment cycle’ (7-weeks of imiquimod and cryosurgery at days 24 and 28 of the treatment cycle) a partial response of the tumor was achieved. Panel (C): The tumor area after the second treatment cycle of 5 weeks imiquimod and 1 cryosurgery session (‘5/1 cycle’). Panel (D): Sustained complete clearance at 30-month follow up.

(0,19MB).

Patient 2 initially presented with two cSCC (Tumors 2 and 3) which responded completely after parallel treatments with ‘7/2 immunocryosurgery cycles’ and two intralesional methotrexate injections (2.5mg pro tumor and pro session at the cryosurgery days). Two smaller cSCC (Tumor 4 and 5) diagnosed during follow-up were treated with one standard ‘5/1 immunocryosurgery cycle’ each and adjuvant tretinoin cream. Relapses were not recorded for at least 12 months.

Patient 3 (Fig. 2) developed an intense inflammatory reaction after the first cryosurgery session of the ‘7/2 immunocryosurgery cycle’ with adjuvant 5mg intralesional methotrexate and did not consent to it at the 2nd cryosurgery session at week 4. Instead, an additional week of imiquimod was scheduled to complete a ‘5/1week’ immunocryosurgery cycle’. The tumor responded partially (Fig. 2B) and at one-month follow-up a second ‘5/1 immunocryosurgery cycle’ without adjuvants resulted to complete tumor clearance (Fig. 2C) that persisted after 12 months follow up (Fig. 2D). At six months follow-up a second cSCC was diagnosed and treated with a ‘7/2 immunocryosurgery cycle’ with adjuvant methotrexate at the first cryosurgery session (Day 14). Subsequently the patient was lost to follow-up.

Figure 2.

Panel (A). Initial presentation of the Tumor 6 (Patient 3) in the midscalp. An intense inflammatory response after the first cryosurgery session of the ‘7/2 treatment cycle’ Panel (B). Tumor rests at the end of the first treatment cycle. Only partial response was noted. Panel (C). The tumor area at the end of the second treatment cycle. Panel (D) The tumor site at the 12-month follow-up. The healing process is excellent in an area that normally requires complex surgical reconstruction procedures.

(0,34MB).

Patient 4 presented with a rapidly growing cSCC on his left cheek (Table 1). He initially denied surgical excision or radiotherapy. However, the neoplasm responded only partially to 14 weeks imiquimod application, 5 sessions of cryosurgery and 5 intralesional methotrexate injections (Table 1). Subsequently he consented to radiotherapy and remained tumor free at the six months follow-up.

In total, from the eight cSCC, seven responded completely to augmented, time protracted and adjuvant-enhanced immunocryosurgery cycles. From these initially responders six tumor sites remained relapse-free for at least 12 months after treatment.

To date, immunocryosurgery has been successfully applied to treat BCC,5 Bowen's disease6 and lentigo maligna.7 Immunocryosurgery was not considered a treatment option for cSCC, as cryosurgery ranks third line, mainly palliative modality, and imiquimod is not suggested for cSCC.3 However, the lasting efficacy of immunocryosurgery in the case of BCC is indicative of a synergistic interaction of imiquimod and cryosurgery within the proposed timing scheme with an underlying activation of immunostimulatory mechanisms both at tissue and at systemic levels.8

Surgery is not generally contraindicated in the oldest old although due to co-existing frailty often a not fully guideline-concordant surgical treatment may be applied.9

Conclusively, in this age group minimally invasive procedures, immunocryosurgery-based schemes or immunocryosurgery-like combinations of topicals (imiquimod, tretinoin cream and 2% 5-fluoruracil solution) with cryosurgery10 offer the advantage of flexible approach to individualized treatment needs to improve feasibility and effectiveness with minimal treatment burden.

Conflict of interests

The authors declare that they have no conflict of interest.

Acknowledgements

The authors wish to express their appreciation to Professor Petia Radeva for language editing.

References
[1]
G.R. Williams, A. Mackenzie, A.A. Magnuson, R. Olin, A. Chapman, S. Mohile, et al.
Comorbidity in older adults with cancer.
J Geriatr Oncol, 7 (2016), pp. 249-257
[2]
A.C. Green, C.M. Olsen.
Cutaneous squamous cell carcinoma: an epidemiological review.
Br J Dermatol, 177 (2017), pp. 373-381
[3]
A.J. Stratigos, C. Garbe, C. Dessinioti, C. Lebbe, V. Bataille, L. Bastholt, et al.
European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2.
Treat Eur J Cancer, 128 (2020), pp. 83-102
[4]
H.S. Lin, J.N. Watts, N.M. Peel, R.E. Hubbard.
Frailty and post-operative outcomes in older surgical patients: a systematic review.
BMC Geriatr, 16 (2016), pp. 157
[5]
G. Gaitanis, I.D. Bassukas.
Immunocryosurgery for non-superficial basal cell carcinomas20mm in maximal diameter: five-year follow-up.
J Geriatr Oncol, (2019), pp. 475-478
[6]
G. Gaitanis, I.D. Bassukas.
Immunocryosurgery – an effective combinational modality for Bowen's disease.
Dermatol Ther, 29 (2016), pp. 334-337
[7]
M. Oro-Ayude, B. Gonzalez-Sixto, J.M. Faraldo-Lorenzo, C. Feal, A. Flórez.
Periocular lentigo maligna successfully treated with immunocryosurgery.
Dermatol Ther, 34 (2021), pp. e14561
[8]
G. Gaitanis, A. Ganiatsa, G. Vartholomatos, A. Karamoutsios, P. Pappas, I.D. Bassukas.
Immunocryosurgery for basal cell carcinoma: impact on circulating CD4+CD25 high T regulatory cells and serum cytokines.
Eur J Dermatol, 30 (2020), pp. 605-606
[9]
C.E. DeSantis, K.D. Miller, W. Dale, S.G. Mohile, H.J. Cohen, C.R. Leach, et al.
Cancer statistics for adults aged 85 years and older, 2019.
CA Cancer J Clin, 69 (2019), pp. 452-467
[10]
R. Fayne, S. Nanda, A. Nichols, J. Shen.
Combination topical chemotherapy for the treatment of an invasive cutaneous squamous cell carcinoma.
J Drugs Dermatol, 19 (2020), pp. 202-204
Copyright © 2022. AEDV
Idiomas
Actas Dermo-Sifiliográficas

Suscríbase a la newsletter

Opciones de artículo
Herramientas
es

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?